NCT02537444View on ClinicalTrials.gov

Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

PHASE2CompletedINTERVENTIONAL

Enrollment

78

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

October 31, 2018

Conditions

Ovarian Cancer

Interventions

DRUG

Acalabrutinib

DRUG

acalabrutinib and pembrolizumab combination

Trial Locations (2)

19104

Jordan Center For Gynecologic Cancer At Penn, Philadelphia

Unknown

Arizona Gynecology Oncology, Tucson

Sponsors

Lead Sponsor

Acerta Pharma BV

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Acerta Pharma BV

INDUSTRY